Income Statement Bruker Corporation
Equities
BRKR
US1167941087
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.03 USD | -0.72% |
|
-2.04% | -18.07% |
| Nov. 24 | Bruker Corporation acquired AST Revolution, LLC from Indaba Capital Management, L.P. | CI |
| Nov. 24 | Bruker Buys AST Revolution | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.98B | 2.41B | 2.52B | 2.95B | 3.37B | |||||
Other Revenues, Total | 6M | 7.4M | 6.2M | 13.1M | - | |||||
Total Revenues | 1.99B | 2.42B | 2.53B | 2.96B | 3.37B | |||||
Cost of Goods Sold, Total | 1.04B | 1.2B | 1.22B | 1.45B | 1.68B | |||||
Gross Profit | 944M | 1.21B | 1.31B | 1.52B | 1.68B | |||||
Selling General & Admin Expenses, Total | 472M | 563M | 608M | 730M | 892M | |||||
Stock-Based Compensation (IS) | - | 2.7M | - | - | - | |||||
R&D Expenses | 198M | 221M | 236M | 295M | 376M | |||||
Other Operating Expenses | 8.4M | 1.2M | 6.2M | 10.9M | 3.8M | |||||
Other Operating Expenses, Total | 678M | 788M | 850M | 1.04B | 1.27B | |||||
Operating Income | 266M | 426M | 456M | 484M | 410M | |||||
Interest Expense, Total | -14.4M | -14.3M | -16.1M | -16.4M | -47.9M | |||||
Interest And Investment Income | 3.2M | 900K | 4.1M | 7.5M | 9.3M | |||||
Net Interest Expenses | -11.2M | -13.4M | -12M | -8.9M | -38.6M | |||||
Income (Loss) On Equity Invest. | - | - | 1M | 2M | -1.7M | |||||
Currency Exchange Gains (Loss) | -8M | -4.1M | -5.8M | -13.3M | 23.7M | |||||
Other Non Operating Income (Expenses) | - | - | - | -3.1M | - | |||||
EBT, Excl. Unusual Items | 247M | 409M | 440M | 461M | 394M | |||||
Restructuring Charges | -15.8M | -8.2M | -4.8M | -25.5M | -31.9M | |||||
Merger & Related Restructuring Charges | -3.2M | -6.8M | -19.7M | -11.7M | -119M | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | -11.4M | -24.6M | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | -2.1M | 500K | -300K | -2.5M | -2.2M | |||||
Insurance Settlements | - | - | - | - | - | |||||
Other Unusual Items | - | -500K | - | 136M | -11.2M | |||||
EBT, Incl. Unusual Items | 226M | 394M | 415M | 546M | 205M | |||||
Income Tax Expense | 64.4M | 113M | 116M | 118M | 91.4M | |||||
Earnings From Continuing Operations | 161M | 281M | 298M | 428M | 114M | |||||
Net Income to Company | 161M | 281M | 298M | 428M | 114M | |||||
Minority Interest | -3.6M | -3.5M | -1.9M | -1.3M | -700K | |||||
Net Income - (IS) | 158M | 277M | 297M | 427M | 113M | |||||
Net Income to Common Incl Extra Items | 158M | 277M | 297M | 427M | 113M | |||||
Net Income to Common Excl. Extra Items | 158M | 277M | 297M | 427M | 113M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.03 | 1.83 | 2 | 2.92 | 0.76 | |||||
Basic EPS - Continuing Operations | 1.03 | 1.83 | 2 | 2.92 | 0.76 | |||||
Basic Weighted Average Shares Outstanding | 153M | 151M | 149M | 146M | 149M | |||||
Net EPS - Diluted | 1.02 | 1.81 | 1.99 | 2.9 | 0.76 | |||||
Diluted EPS - Continuing Operations | 1.02 | 1.81 | 1.99 | 2.9 | 0.76 | |||||
Diluted Weighted Average Shares Outstanding | 155M | 153M | 149M | 147M | 150M | |||||
Normalized Basic EPS | 0.98 | 1.66 | 1.84 | 1.96 | 1.65 | |||||
Normalized Diluted EPS | 0.97 | 1.65 | 1.83 | 1.95 | 1.64 | |||||
Dividend Per Share | 0.16 | 0.16 | 0.2 | 0.2 | 0.2 | |||||
Payout Ratio | 15.59 | 8.73 | 10.05 | 6.88 | 26.7 | |||||
Supplemental Items | ||||||||||
EBITDA | 346M | 515M | 545M | 599M | 594M | |||||
EBITA | 302M | 464M | 494M | 531M | 509M | |||||
EBIT | 266M | 426M | 456M | 484M | 410M | |||||
EBITDAR | 375M | 544M | 570M | 639M | 651M | |||||
Total Revenues (As Reported) | 1.99B | 2.42B | 2.53B | 2.96B | 3.37B | |||||
Effective Tax Rate - (Ratio) | 28.52 | 28.71 | 28.05 | 21.55 | 44.54 | |||||
Current Domestic Taxes | -1M | 2.2M | -7.9M | 4.7M | 11M | |||||
Current Foreign Taxes | 85.4M | 118M | 135M | 139M | 144M | |||||
Total Current Taxes | 84.4M | 120M | 127M | 143M | 155M | |||||
Deferred Domestic Taxes | -5.9M | -10.3M | -4.8M | -22.9M | -49.5M | |||||
Deferred Foreign Taxes | -14.1M | 3.1M | -6.2M | -2.8M | -14.3M | |||||
Total Deferred Taxes | -20M | -7.2M | -11M | -25.7M | -63.8M | |||||
Normalized Net Income | 151M | 252M | 273M | 287M | 245M | |||||
Interest on Long-Term Debt | 14.4M | 14.3M | 16.1M | 16.4M | 47.9M | |||||
Non-Cash Pension Expense | 3.3M | 2.3M | 1M | 100K | -1.3M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 9.7M | 13.8M | 19.3M | 23.7M | 27.8M | |||||
Research And Development Expense From Footnotes | 198M | 221M | 236M | 295M | 376M | |||||
Net Rental Expense, Total | 28.7M | 29.2M | 24.3M | 40M | 56.9M | |||||
Imputed Operating Lease Interest Expense | 3.53M | 2.79M | 2.32M | 3.9M | 12.03M | |||||
Imputed Operating Lease Depreciation | 25.17M | 26.41M | 21.98M | 36.1M | 44.87M | |||||
Stock-Based Comp., COGS (Total) | 2M | 2.2M | 1.1M | 1.4M | 1.9M | |||||
Stock-Based Comp., R&D Exp. (Total) | 2M | 2.2M | 1.3M | 1.9M | 2.7M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 9.3M | 10.1M | 13.3M | 15.1M | 17.1M | |||||
Stock-Based Comp., Other (Total) | 2.7M | 2.7M | 12M | 5.6M | 3.6M | |||||
Total Stock-Based Compensation | 16M | 17.2M | 27.7M | 24M | 25.3M |
- Stock Market
- Equities
- BRKR Stock
- Financials Bruker Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















